Notch Therapeutics raises $85M for cancer treatments and plans to open Seattle location

Canada-based Notch Therapeutics announced its plans to open a Seattle research laboratory as part of its U.S. expansion, following a recent Series A funding round that raised $85 million. The company, which develops stem cell-derived immunotherapies for cancer, was founded in 2018 and has offices in Vancouver, B.C. and Toronto. It will join the ranks of other local immunotherapy life science companies including Sana Biotechnology, Chinook Therapeutics, Adaptive Biotechnologies, and others.